Sepantronium

Advances in understanding lymphoma's molecular biology have identified potential therapeutic targets, leading to new agents like monoclonal antibodies and small-molecule inhibitors. Despite progress, drug development remains slow, with challenges in identifying 'driver' molecular defects and predictive biomarkers. The review highlights the need for focused research to accelerate the approval of promising drugs for lymphoma treatment.